Project Details
Description
A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (?50years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses an
| Status | Active |
|---|---|
| Effective start/end date | 6/21/23 → 6/30/33 |
Funding
- GLAXOSMITHKLINE
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.